Background and Purpose: Transcranial color-coded real-time sonography has been developed as a promising new bedside procedure to monitor central nervous system parenchymal and vascular pathology; the present study was designed to investigate the potential role of galactose microparticles (SH U 508 A) as a new ultrasound contrast-enhancing agent for transcranial sonography.
T ranscranial color-coded real-time sonography (TCCS) has evolved during the 3 years since our original publication'; not only vascular pathology2'3 but also central nervous system (CNS) tumors,4 arteriovenous malformations,24 and hydrocephalus5 may be disclosed. There are some clear advantages over conventional transcranial pulsed-wave Doppler sonography: rapid visual identification of large intracranial vessels, resulting in shorter examination times; real-time localization of vascular pathology by color imaging within the black-and-white B-mode image of the parenchyma; and detection of parenchymal lesions with new diagnostic information, thus complementing computed tomographic and magnetic resonance imag-ing findings.4 The latter may become especially valuable for neurosurgical procedures, enabling preoperative, intraoperative, and postoperative imaging without patient discomfort and risk. However, color imaging is still expensive, and whether higher costs are balanced by these advantages is unclear. Vascular lesions represent the main application of transcranial ultrasound examinations so far; this applies primarily to the detection of vasospasm and intracranial occlusive lesions.6'7 As a real-time imaging system, TCCS would have the potential for real-time 3-dimensional vascular color imaging, provided fine resolution could be improved. A substantial increase in vascular fine resolution might be achieved by agents that result in enhanced reflection of the ultrasound beam: among others, microparticle-based ultrasound contrast agents8 lead to a transient increase in blood echodensity after intravenous injections and presently are most frequently used in cardiology (contrast echocardiography).9"0 More recently, the use of intravenous echo contrast agents in color Doppler was reported to lead to the expected substantial increase in Doppler signal intensity; consequently, the signal-tonoise ratio was improved and the sensitivity increased." However, application was limited to the venous system and right heart cavities because of rapid degradation of microspheres during pulmonary transit; a contrast agent for application within the arterial system would require pulmonary stability. Several concepts of microbubble stabilization have been reported8; so far, only two have provided transpulmonary contrast effects, air-filled microspheres of human albumin9 and the galactose microparticles SH U 508 A.'2'3 SH U 508 A was reported to substantially improve left-heart color Doppler examination'4; because preliminary animal experiments had already shown feasibility and tolerance of galactose microspheres for transcranial Doppler,'4 we concluded that there should be great potential for its use in transcranial color and Doppler imaging. We therefore investigated the capacity of this new ultrasound contrast agent to improve the fine resolution of transcranial color imaging in a phase-two clinical study.
Subjects and Methods

Patients
This phase-two clinical study had been approved by the ethical committees of the University of Wurzburg, FRG, and the Free University of Berlin. The aim of this study was to test the potential echo signal enhancement of SH U 508 A (Schering AG, Berlin), a new galactose microparticle suspension, in transcranial color-coded real-time sonography. Ten patients were enrolled in this study; because of arterial or venous vascular lesions, Doppler examinations were necessary in these patients (conventional examination would have disclosed insufficient signal intensity). Exclusion criteria comprised galactosemia, pregnancy, age below 18 years, critically ill patients, recent myocardial infarcts, unrelated treatment that induced significant laboratory abnormalities, and examination with x-ray contrast agents 48 hours before this study. All displayed in real time as color signals within a subsector of the black-and-white image (flow toward the probe was in red/yellow, and flow away from the probe was in blue/turquoise). Further details are described in Reference 1. Examinations were performed through transtemporal bone windows.' Transforaminal examinations were performed from a nuchal position, aiming through the foramen magnum to the clivus (axial planes). Supratentorial investigations were done as coronal and axial scans.1
Results
General Results
In all 10 patients, SH U 508 A was tolerated without any side effects or subjective discomfort. No laboratory or electrocardiographic changes occurred during or after the examinations. General results for all 10 patients are shown in Table 1 . The mean time to contrast appearance was 23 (range, 16-38) seconds, and the average time with lasting contrast effects was 325.5 (range, 44-630) seconds. The data did not seem to be clearly age or sex related (analysis not presented, as the number of patients was limited). Strong enhancement of color-coded vascular imaging and Doppler signals could be observed. Patient 3 could not be insonated before application of SH U 508 A. For all patients, 300 mg/mL and 400 mg/mL SH U 508 A represented the optimal concentrations; with 200 mg/ mL, signal enhancement was only moderate. If injections were performed too rapidly (< <20 seconds), SH U 508 A produced color artifacts due to excessive signal enhancement during its first circulatory passage (according to the protocol, the gain was required to be kept constant throughout the examination). For all patients, cerebral angiograms (catheter digital subtraction angiography) were correlated to CE-TCCS Stroke Vol 24, No 5 Mar 1993 .5i
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-U Table 2 . indicate that peripheral branches of the large cerebral arteries are disclosed by SH U 508 A in the majority of patients; this may be especially pronounced for middle and posterior cerebral arteries (Figure 2 ). The upper part of the basilar artery (basilar head) could be analyzed in all 10 patients. Cerebral veins were examined in this study in only seven patients; in all of these the inferior sagittal sinus, the internal cerebral veins, the great internal cerebral vein (Galen's vein), and the straight sinus could be visualized after application of SH U 508 A (Figure 3 ). The confluence (Figure 4 ; torcular herophili) was not detected in all patients because of geometrical problems (the phased-array system did not reach this far backward into the posterior fossa).
Transtemporal Coronal Scans
Seven patients could be evaluated for transtemporal coronal examinations (Table 3) . Peripheral branches of the anterior cerebral artery were not detected regularly; in approximately half of the cases, peripheral branches of middle and posterior arteries, as well as the superior cerebellar artery, were visualized. The same applies to the inferior sagittal sinus. The main finding was an unequivocal delineation of the basilar artery in its upper third and the posterior cerebral arteries in their P1 and P2 segments ( Figure 5 ) in the majority of cases.
Tr-ansforanminma Approach of the Vertebrobasilar System
The transforaminal examination of the vertebrobasilar svstem could be performed only in four patients; however, these findings were clear cut (Table 4) . In all four patients the vertebral arteries (V3 and V4), the infratentorial section of the basilar artery and the posterior inferior cerebellar, anterior inferior cerebellar, and superior cerebellar arteries could be delineated The intracerebral venous system seemed to be almost inaccessible to Doppler techniques because of low venous flow velocities and anatomical barriers, among other reasons. Recently Aaslid et a117 demonstrated examination of the straight sinus in a methodological study of cerebral autoregulation. TCCS could only rarely display venous flow, as was the case in all seven patients in our study that were investigated (Table 2 ). However, after SH U 508 A contrast application, all deep venous structures could be visualized and also clearly separated from nearby arterial flow phenomena. In all but patient 10 (in whom no angiogram was performed), angiographies were taken for correlation. Although we could demonstrate the inferior sagittal sinus through a transvertical approach in a single case (not presented here), we are still unable to detect cortical venous flow, even from the superior sagittal sinus. Due to the phased-array technique required for transcranial imaging, anatomically distant structures such as the transverse sinus still remain inaccessible.
In conclusion, the new transpulmonary ultrasound contrast agent SH U 508 A has clearly opened new perspectives for transcranial color-coded real-time sonography by enlarging the spectrum of arterial and venous cerebral vessels that may be reproducibly examined. Contrast application also seems to enable transcranial ultrasound examinations in those patients who previously could not be insonated because of insufficient bone windows. This preliminary study has also disclosed the advantage of a transcranial color-coded real-time system over conventional transcranial Doppler, as only TCCS will be able to analyze all detailed data from a three-dimensional vascular image in a reasonable fashion. But a number of new questions arise at the same time, and potential areas of future investigation include reproduction of these findings in a larger series, delineation of the optimal regimen of contrast application, and definition of indications for specific disease categories in which ultrasound contrast agents clearly have some diagnostic benefit for our patients. In addition, whether contrast-enhanced transcranial Doppler techniques are reliable methods for evaluation of small intracranial arterial vessels and veins remains to be investigated.
